Anika Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANIK research report →
Range $21 – $21
Price Chart
About the company
Anika Therapeutics, Inc. is a company dedicated to joint preservation, innovating and providing early intervention orthopedic care across the globe, including the United States and Europe. Their core focus areas include osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and advanced bone-preserving joint technologies.
- CEO
- Stephen D. Griffin
- IPO
- 1993
- Employees
- 235
- HQ
- Bedford, MA, US
Get TickerSpark's AI analysis on ANIK
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $177.22M
- P/E
- -102.16
- Fwd P/E
- 11.92
- PEG
- -0.34
- P/S
- 1.44
- P/B
- 1.29
- EV/EBITDA
- 30.56
- Div Yield
- 0.00%
- Gross Margin
- 63.40%
- Op Margin
- -2.11%
- Net Margin
- -1.43%
- ROE
- -1.28%
- ROIC
- -0.41%
Latest fiscal year · YoY change
- Revenue
- $112.82M-5.9%
- Gross Profit
- $63.81M-16.0%
- Op Income
- $-11,051,000
- Net Income
- $-10,880,000+80.7%
- EPS
- $-0.76+80.2%
- OCF Growth
- +107.1%
- FCF Growth
- +287.1%
- 52W High
- $22.88
- 52W Low
- $9.01
- 50D MA
- $18.88
- 200D MA
- $16.50
- Beta
- 0.20
- RSI (14)
- 28
- Avg Volume
- 105.68K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Anika delivered 10% Q3 revenue growth, stronger margins, and raised full-year guidance, while also laying out continued investment in manufacturing and its HA pipeline.· November 6, 2026
- Q3 total revenue rose 10% to $30.6 million, with commercial up 17% to $14 million and OEM up 5% to $16.6 million.
- Gross margin improved to 62% from 56% a year ago, though it was down from 65% in Q2 due mainly to product mix, including HYALOMATRIX.
- Integrity continued to scale, growing more than 30% year over year and bringing year-to-date growth to 37%.
- The company signed a new 10-year Hyvisc distribution deal with Boehringer Ingelheim that is expected to bring $8 million in payments, including a $4 million upfront payment in Q1 2027.
- Management raised 2026 revenue growth and adjusted EBITDA margin guidance and said CINGAL NDA filing is now expected before year-end 2027.
Total revenue was $30.6 million, up 10% from $27.8 million a year ago. Commercial channel revenue grew 17% to $14 million, while OEM revenue rose 5% to $16.6 million. Gross margin was 62% versus 56% last year and 65% in Q2. GAAP operating loss narrowed to $700 thousand from $3.2 million, and GAAP loss from continuing operations was $300 thousand, or $0.02 per share, versus a loss of $3.2 million, or $0.22 per diluted share. Adjusted net income from continuing operations was $3.9 million, or $0.29 per diluted share, and adjusted EBITDA was $5.1 million versus $900 thousand last year and $7.1 million in Q2. Cash and cash equivalents were $45 million at September 30, up from $38.4 million at June 30. For 2026, management raised total company revenue growth guidance to 6% to 10% from 5% to 10%, OEM growth guidance to 5% to 9% from 0% to 5%, and commercial growth guidance to 9% to 13% from 12% to 18%. It also raised adjusted EBITDA margin outlook to 15% to 17% from 13% to 17%. For 2027, management reaffirmed total company revenue growth of flat to 5%, later clarifying commercial growth as 5% to 15% and OEM as flat to modestly lower; forward guidance excludes U.S. HYALOFAST sales.
Steve Griffin framed the quarter as further evidence that Anika is becoming a stronger and more profitable company, emphasizing progress across the core hyaluronic acid platform. He highlighted three priorities: sustainable revenue growth, operational discipline, and advancing the innovation pipeline. His tone was constructive and confident, but he acknowledged that margin improvement may not be linear because of mix and pricing pressure in U.S. OA pain markets. He also stressed that the company will keep investing in manufacturing capacity and in products and partnerships where it sees the best return.
Ian McLeod emphasized that the quarter showed continued revenue and margin progress, with operating expenses at $19.5 million, up 4%, R&D at $7.9 million, and SG&A at $11.7 million. He pointed to $8.4 million of operating cash in the quarter, $1.7 million of CapEx, and $45 million in cash at quarter-end, saying the balance sheet gives flexibility for manufacturing and development investment. He also said full-year 2026 profitability expectations improved, with the adjusted EBITDA impact from regenerative solutions now expected to be closer to $8 million rather than $10 million thanks to expense discipline. On capital allocation, he said priority one is CapEx for manufacturing, followed by investment in the regenerative solutions team, while other uses such as share repurchases or M&A remain possible later.
Analysts pressed management on gross margin durability, 2027 OA pain pricing pressure, the scope of the CINGAL CMC work, the new Hyvisc agreement, fourth-quarter revenue assumptions, Integrity adoption, cash generation, and potential capital deployment. Management said gross margin should roughly stay in the low 60s near term, with possible upside from manufacturing gains offset by U.S. pricing pressure. They said pricing declines are expected next year and are embedded in guidance, and clarified that CINGAL’s CMC work is about bringing manufacturing controls up to drug-product standards before NDA filing. On capital allocation, management said the $4 million Hyvisc upfront payment is included in guidance and reiterated that CapEx and internal investment are the first priorities, with buybacks or M&A only considered further down the list.
The bull case from the call is that revenue growth is broadening across both commercial and OEM, with Integrity, international OA pain, and OEM partnerships all contributing. Management also showed tangible operating leverage: gross margin improved year over year, adjusted EBITDA rose sharply, and the balance sheet strengthened to $45 million in cash.
The main risks are U.S. OA pain pricing pressure, seasonal softness in elective procedures, and the fact that Q4 growth is expected to be more moderate than prior years. The FDA said HYALOFAST PMA is not approvable based primarily on the clinical data submitted, and management is still assessing next steps, while CINGAL still has meaningful CMC work to complete before an NDA can be filed.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 93.7%
- Shares Outstanding
- 13.40M
- Float Shares
- 12.55M
of shares held by institutions
135 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for ANIK, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Caligan Partners LP | 1.44M | 0 |
| Blackrock, Inc. | 1.41M | ▼ 38.60K |
| Vanguard Group Inc | 779.16K | ▼ 1.50K |
| Morgan Stanley | 626.37K | ▲ 12.05K |
| Acadian Asset Management LLC | 606.54K | 0 |
| Vanguard Capital Management LLC | 565.91K | ▼ 6.21K |
| Boothbay Fund Management, LLC | 529.63K | ▼ 14 |
| Dimensional Fund Advisors LP | 461.86K | ▲ 10.77K |
| Renaissance Technologies LLC | 458.72K | ▼ 22.70K |
| Geode Capital Management, LLC | 419.17K | ▲ 87.59K |
| Aqr Capital Management LLC | 400.99K | ▼ 158.86K |
| Capital Management Corp /Va | 379.44K | ▼ 69.04K |
Held by 134 ETFs
Biggest fund positions in ANIK by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 4, 26 | Fischetti Gary P | buy | 1,000 |
| Aug 3, 26 | Fischetti Gary P | buy | 1,000 |
| Jun 18, 26 | Fischetti Gary P | other | 10,402 |
| Jun 18, 26 | HENNEMAN JOHN B III | other | 10,402 |
| Jun 18, 26 | Richard Stephen | other | 10,402 |
| Jun 18, 26 | Capper Joseph H | other | 10,402 |
| Jun 18, 26 | CONLEY SHERYL L | other | 10,402 |
| Jun 3, 26 | Griffin Stephen D. | other | 12,840 |
| Jun 3, 26 | Griffin Stephen D. | other | 3,769 |
| Jun 3, 26 | Griffin Stephen D. | other | 12,840 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our ANIK coverage
Recent articles, reports, and earnings notes.
No research on ANIK yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANIK report →Anika Therapeutics, Inc. (ANIK) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
What Anika Therapeutics (ANIK) Said on Its Q3 Earnings Call
marketbeat.com · Nov 6
Anika Therapeutics (ANIK) Beats Q3 Earnings and Revenue Estimates
zacks.com · Nov 6
Anika Reports Third Quarter 2026 Financial Results
globenewswire.com · Nov 6
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
globenewswire.com · Oct 22
Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
zacks.com · Sep 25
Xencor (NASDAQ:XNCR) versus Anika Therapeutics (NASDAQ:ANIK) Head-To-Head Contrast
defenseworld.net · Sep 18
Corient Private Wealth LP Takes Position in Anika Therapeutics Inc. $ANIK
defenseworld.net · Sep 8
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.